Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
about
Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.Gemcitabine-induced cardiomyopathy: a case report and review of the literature.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease.Mantle cell lymphoma: a biological and therapeutic paradigm.HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaChemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study.Gemcitabine and acute myocardial infarction--a case report.Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase.Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry.Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients.Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
P2860
Q24813078-353660C2-5121-4649-9FEE-25E1E2D7928BQ33343492-E8F65121-29CE-4C95-A5BE-C6AD0420BD79Q33383608-2D466AF2-6BE2-4B6A-8226-3EE045DECF76Q33394153-F8B4A700-4152-48DB-B442-992E2C384D72Q33396261-8AD73725-FCC4-4E7B-BEC3-AA4371839C94Q33402306-8498CB45-7BA8-4C20-8288-A8499B5F57D9Q33863038-003877D4-AB23-44A8-9113-9EEEB77F0368Q34122035-CC0C454C-5C50-4DDA-9543-456A3FF37FC3Q34155353-395E067E-8698-4AA9-9D71-8013F27D0A0DQ34769876-986B8769-43F5-42BC-8BE5-40890414E412Q35483623-504199EE-CF41-4B9A-BFB4-5717C98A8583Q35563035-FF3E5299-B1FD-47C3-8082-986DC803FD4AQ36480065-9CE035B3-8300-408C-B274-E1DCEA63C162Q38221083-DBB6E264-2D2B-4391-B00A-3C7547B1E525Q38631350-B273C644-1ABB-44A3-951A-047EB4F13569Q38768797-99F72475-8448-4895-931C-0E49C7C53A68Q38878964-6799809F-595A-4932-8BEC-A526F1ABFF9EQ43814680-A293BFD9-2E2F-4905-9D4F-45F387A78692Q45141158-041362FF-6AA1-46F3-A147-3DDB35D31735Q46909218-316C7424-F60B-440C-B5C2-33FAB93B97D6Q48246246-807D6E3B-FE3B-4F3C-803C-F010F7975D07Q53153689-C88E35D9-158D-4C7C-AB72-7CC0B0B630B6Q54494358-35342C40-F5E4-45C1-BF6B-CDACA63E1DD4
P2860
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@ast
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@en
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@nl
type
label
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@ast
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@en
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@nl
prefLabel
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@ast
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@en
Gemcitabine as a single agent ...... -grade non-Hodgkin's lymphoma.
@nl
P2093
P2860
P1476
Gemcitabine as a single agent ...... w-grade non-Hodgkin's lymphoma
@en
P2093
B Coiffier
C Thieblemont
E Bourgeois
F Morschhauser
P Solal-Celigny
P2860
P304
P356
10.1046/J.1365-2141.2001.02795.X
P407
P577
2001-06-01T00:00:00Z